


08 141914
1/8/12(3-methyl-TTNCB)
STANDARDIZED AGONIST DOSE RESPONSE

2/12

(ALL TRANS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE






Fig. 2

(9CIS RETINOIC ACID)
STANDARDIZED AGONIST DOSE RESPONSE



(3-methyl-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE



(3-bromo-TTNEB)
STANDARDIZED AGONIST DOSE RESPONSE





Fig. 5



(3-methyl-TTNCHBP)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 6

- pRShRAR-alpha (wt)
- pRShRAR-beta (wt)
- pRShRAR-gamma (wt)
- pRSmRXR-alpha (wt)
- pRSmRXR-beta (wt)
- pRSmRXR-gamma (wt)

(3-methyl-TTNEHBP)
STANDARDIZED AGONIST DOSE RESPONSE




Fig. 7




Fig. 8




Fig. 9

EFFECT OF RETINOIDS ON RAT HDL CHOLESTEROL




Figure 10

Myeloma RPMI-8226 Cell Proliferation




Figure 12




Figure 11